Date: 26 Feb 2009
Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Zoledronate is a promising bisphosphonate that improves the bone mineral density by 0.69 standard deviations in thalassemia-induced osteoporosis, but the entire range of its actions and side effects is currently not fully understood.
Zoledronate is a promising bisphosphonate for the treatment of thalassemia-induced osteoporosis; however, a quantitative summary of its beneficial effect and its effects on the markers of bone turnover are not established.
We conducted a meta-analysis of the published randomized controlled trials using standardized mean difference and a random effects model for improvement in bone mineral density (BMD). We also conducted a systematic review for the influence of zoledronate on markers of bone turnover and bone pain.
We found that zoledronate improves the baseline BMD by 0.69 (95% confidence interval 0.47–0.90) standard deviations—an effect that was more pronounced when BMD was measured at the lumbar spine. However, the mechanistic interpretations of the effects on the markers of bone turnover are not completely clear.
Sufficient evidence exists to demonstrate that 4 mg zoledronate given every 3 months markedly improves the BMD; however, more qualitative and quantitative evidence is required to understand the mechanisms of its action and the potential side effects.
Johanson NA (1990) Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am 21:191–198PubMed
Voskaridou E, Stoupa E, Antoniadou L, Premetis E, Konstantopoulos K, Papassotiriou I, Terpos E (2006) Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica 91:813–816PubMed
Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 11(Suppl 3):975–977PubMed
Gaudio A, Morabito N, Xourafa A, Macri I, Meo A, Morgante S, Trifiletti A, Lasco A, Frisina N (2008) Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J Endocrinol Invest 31:181–184PubMed
Mahachoklertwattana P (2006) Zoledronic acid for the treatment of thalassemia-induced osteonecrosis. Haematologica 91:1155APubMed
Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 91:1193–1202PubMed
Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93:1588–1590CrossRefPubMed
Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, Erten S, Tuck S, Agnew JE, Raja K, Davies K, Hoffbrand AV (1998) Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 11(Suppl 3):795–801PubMed
USFDA (2008) Information for Healthcare Professionals. http://www.fda.gov/cder/drug/InfoSheets/HCP/bisphosphonatesHCP.htm
USFDA (2008) Early Communication of an Ongoing Safety Review. http://www.fda.gov/cder/drug/early_comm/bisphosphonates.htm
Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:1799–1809 nihpa40967CrossRefPubMed
Toumba M, Sergis A, Kanaris C, Skordis N (2007) Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev 5:642–648PubMed
Derchi G, Bellone P, Forni GL, Lupi G, Jappelli S, Randazzo M, Zino V, Vecchio C (1992) Cardiac involvement in thalassaemia major: altered atrial natriuretic peptide levels in asymptomatic patients. Eur Heart J 13:1368–1372PubMed
Patane S, Marte F (2008) Abnormal troponin I levels in a thalassemia major patient with high ferritin concentration, permanent atrial fibrillation and without acute coronary syndrome. Int J Cardiol doi:10.1016/j.ijcard.2008.06.039
- Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review
Volume 21, Issue 1 , pp 183-187
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors